ArticleFrontiers in cardiovascular medicine2026
Systemic inflammation and the risk of adverse clinical outcomes in heart failure with preserved ejection fraction.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Systemic inflammation is implicated in the pathogenesis of cardiovascular disease, including heart failure (HF). We examined the association between systemic inflammation, indicated by elevated high-sensitivity C-reactive protein (hsCRP), and adverse clinical outcomes in individuals with HF with preserved ejection fraction (HFpEF). Methods: This retrospective cohort study identified individuals with HFpEF from the Komodo Healthcare Map™ database (01/01/2016 to 12/31/2023) using a validated algorithm. Systemic inflammation status was established by hsCRP testing: with systemic inflammation if ≥1 hsCRP value of 2-10 mg/L and without systemic inflammation if all hsCRP values <2 mg/L. The relationship between hsCRP and risk for HF events, including all-cause mortality, HF hospitalization and urgent HF visits was examined using Cox proportional hazards models with multivariable adjustment. Results: A total of 11,015 individuals with HFpEF and a qualifying hsCRP measurement were identified (mean age 66.4 years; 44% with systemic inflammation). The incidence rate of the composite HF endpoint was 103.2 per 1,000 person-years for those with systemic inflammation versus 83.3 for those without. Systemic inflammation was associated with a 21% increased risk of the composite HF endpoint (HR 1.21, 95% CI 1.11-1.31). Systemic inflammation was associated with increased risk of HF hospitalization (HR 1.17, 95% CI 1.03-1.33) and urgent HF visits (HR 1.21, 95% CI 1.08-1.35) but not all-cause mortality (HR 1.14, 95% CI 0.98-1.32). Conclusion: Systemic inflammation was associated with increased risk of future adverse CV-related outcomes in individuals with HFpEF, highlighting unmet clinical needs for this population and the potential to optimize their care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.